Researchers at John Theurer Cancer Center at Hackensack University Medical Center Study CLL Retreatment with Venetoclax
Retrospective outcomes and safety data study opens potential for additional therapy after initial treatment with BTKi and venetoclax
Research published in Blood Advances with input from John Theurer Cancer Center at Hackensack University Medical Center experts provides a multicenter, international retrospective evaluation of outcomes and safety data for patients with CLL treated with a venetoclax-based regimen in any line of therapy and then retreated with a second venetoclax-based regimen in a later line of therapy. Their noteworthy finding:
- The study reports the largest experience of the venetoclax retreatment strategy in patients with CLL showing high ORR and durability of remissions supporting the clinical practice of venetoclax retreatment which again benefits patients the second time around.
The study included 46 patients with CLL who were retreated with venetoclax. Importantly, 40% of patients had been treated with a BTKi prior.
More patients are requiring treatment of CLL following time-limited venetoclax-based therapy, making these results of high clinical relevance. Currently, there are limited treatments available for patients with CLL who require additional therapy after treatment with both a BTKi and venetoclax (i.e., “double exposed” patients).
Learn more about innovative cancer treatments at John Theurer Cancer Center at Hackensack University Medical Center.